PMID-28340339 – FOXO4-DRI Targeted Apoptosis of Senescent Cells
Baar MP et al. "Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging," Cell, 2017;169(1):132-147.e16. doi:10.1016/j.cell.2017.02.031
Quick Reference
| Property | Value |
|---|---|
| PMID | 28340339 |
| DOI | 10.1016/j.cell.2017.02.031 |
| Year | 2017 |
| Journal | Cell |
| Study Type | Animal in vivo + In vitro |
| Evidence Level | V |
| Sample | Naturally aged mice, chemotherapy-treated mice, senescent cell cultures |
| Peptide(s) Studied | FOXO4-DRI |
Key Findings
- FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction that maintains senescent cell viability — a landmark discovery in senolytic peptide therapy
- Senescent cells survive by sequestering p53 in the nucleus via FOXO4 binding; FOXO4-DRI competitively disrupts this interaction, releasing p53 to trigger intrinsic apoptosis
- FOXO4-DRI selectively induces apoptosis in senescent cells while sparing non-senescent cells — a critical selectivity feature
- In naturally aged mice, FOXO4-DRI administration reversed chemotoxicity-induced senescence, restored fitness, improved fur density, and increased renal function
- In doxorubicin-treated mice (chemotherapy-induced senescence), FOXO4-DRI counteracted liver toxicity and reversed the aging phenotype
- The D-retro-inverso design confers protease resistance and extended in vivo half-life compared to native L-peptides
- Published in Cell — one of the highest-impact journals in biology — establishing FOXO4-DRI as a founding senolytic peptide
Study Design
Combined in vitro mechanistic studies with in vivo efficacy experiments. In vitro: human senescent fibroblasts (IMR90) and non-senescent controls treated with FOXO4-DRI to demonstrate selective apoptosis. In vivo: naturally aged mice (24+ months) and young mice treated with doxorubicin to induce accelerated senescence, followed by FOXO4-DRI treatment. Readouts included senescent cell burden (SA-beta-gal, p16, p21), organ function, physical fitness, and survival.
Limitations
- Mouse model findings require human translation — no human clinical data available
- D-retro-inverso peptides have complex pharmacokinetics that are difficult to predict from mouse data
- Long-term safety of senescent cell clearance is unknown — some senescent cells may serve beneficial roles (wound healing, tumor suppression)
- The extent of senescent cell clearance and optimal treatment duration/frequency not defined
- Cost and manufacturing complexity of D-retro-inverso peptides are barriers to clinical development
Clinical Relevance
This is the landmark paper establishing FOXO4-DRI as a first-in-class senolytic peptide. The selective targeting of senescent cells by disrupting the FOXO4-p53 survival axis represents a novel therapeutic paradigm for aging and cancer chemotherapy side effects. The cancer relevance is twofold: (1) FOXO4-DRI may mitigate chemotherapy-induced senescence and toxicity, and (2) senescent cells in the tumor microenvironment can promote cancer progression through the senescence-associated secretory phenotype (SASP). This paper is foundational for the anti-aging and longevity field.
Related
#research #animal-in-vivo #evidence-level-V #cancer